查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
乳腺癌药物市场-全球行业规模、份额、趋势、机会和预测，2017-2027 年按疗法细分（按化疗药物、激素疗法、靶向疗法、最终用户、地区）
市场调查报告书
商品编码
1228257

乳腺癌药物市场-全球行业规模、份额、趋势、机会和预测，2017-2027 年按疗法细分（按化疗药物、激素疗法、靶向疗法、最终用户、地区）

Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Therapy, By (Chemotherapy Drugs, By Hormone Therapy, By Targeted Therapy, By End User, and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在 2023 年至 2027 年的预测期内，全球乳腺癌治疗市场预计将以惊人的复合年增长率增长。

易患癌症等慢性病的老年人口不断增加，这推动了全球乳腺癌药物市场的增长。

乳腺癌病例的增加促进了市场增长

全球乳腺癌患病率的上升以及许多患者对有效治疗的需求不断增加，预计将推动乳腺癌治疗市场的增长。 乳腺癌被认为是世界上流行的癌症之一，诊断解决方案的改进有望推动市场增长。 对预防医学和早期治疗的需求不断增长，由于其诸多好处，正促使个人进行诊断程序，进一步推动全球乳腺癌药物市场的增长。

政府宣传计划的启动推动市场增长

政府机构发起的乳腺癌筛查计划和公共机构推出的支持计划有望刺激全球乳腺癌药物市场的增长。 根据世界卫生组织的一份报告，及早发现乳腺癌有助于最大限度地降低乳腺癌死亡率并加快乳腺癌患者的生存期。 世界各地的许多政府机构都在鼓励乳腺癌筛查，尤其是在 50 岁以上的女性中。 此类筛查举措和意识计划促进了有效治疗乳腺癌的药物的可用性，并有望在预测期内推动全球乳腺癌药物市场的增长。

不断增长的靶向治疗需求推动市场增长

对于全世界的肿瘤学家来说，治疗乳腺癌是一项艰鉅的任务。 治疗的可用性和选择因患者而异。 靶向治疗优于所有其他治疗，因为它可以精确靶向乳腺癌细胞而不伤害周围的健康细胞。 靶向治疗帮助医疗专业人员克服传统治疗的局限性。 靶向治疗还有助于肿瘤学家专注于预防性而非反应性治疗。 该疗法将提高诊断为晚期乳腺癌患者的治疗效率，进一步促进全球乳腺癌药物市场的增长。

可自定义

TechSci Research 根据预先确定的市场数据为您公司的独特需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场公司（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章产品疗法概述

第二章研究方法论

第 3 章 COVID-19 对全球乳腺癌药物市场的影响

第四章客户反馈

第 5 章执行摘要

第 6 章乳腺癌药物的全球市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按公司分类（2021 年）
    • 按地区
  • 产品市场地图

第七章北美乳腺癌药物市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按国家
  • 北美分析
    • 美国
    • 墨西哥
    • 加拿大

第八章欧洲乳腺癌药物市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按国家
  • 欧洲国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章亚太地区乳腺癌药物市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按国家
  • 亚太国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章南美乳腺癌药物市场展望

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按国家
  • 南美分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章中东和非洲的乳腺癌药物市场前景

  • 市场规模和预测
    • 按金额
  • 市场份额和预测
    • 按治疗方法（化学疗法、激素疗法、免疫疗法、靶向疗法等）
    • 最终用户（医院、专科诊所、门诊手术中心、其他）
    • 按国家
  • MEA：国家分析
    • 南非的乳腺癌药物
    • 沙特阿拉伯的乳腺癌药物
    • 阿联酋的乳腺癌药物

第 12 章市场动态

  • 司机
  • 任务

第13章新兴国家市场趋势与发展

第14章竞争格局

  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly & Company
  • Merck Co. & Inc.
  • GlaxoSmithKline, Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Halozyme Inc.
  • Eisai Co., Ltd.
  • Fresenius Kabi AG

第15章 战略的提言

简介目录
Product Code: 10617

The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. The growing geriatric population who are more susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.

The rising incidences and high prevalence rate of breast cancer across the world are expected to augment the global breast cancer therapeutics market. With this, extensive investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous upgrades help increase understanding of breast cancer at the molecular level, and the introduction of novel solutions has assisted in lowering the breast cancer mortality rate over the past few years. Newly developed therapeutics efficiently slow down the growth and proliferation of cancerous cells, which is projected to boost the global breast cancer therapeutics market in the upcoming years.

Rise in Cases of Breast Cancer Augments the Market Growth

The growing prevalence of breast cancer across the globe and the escalating demand for effective treatment for a large number of patients are expected to stimulate the growth of the breast cancer therapeutics market. Breast cancer is considered one of the prevalent forms of cancer across the world, and enhanced diagnostic solutions are expected to propel market growth. The escalating demand for preventive care and early treatment due to its numerous benefits led individuals to go for diagnostic procedures, further driving the global breast cancer therapeutics market growth.

Launch of Awareness Programs by Government Stimulates the Market Growth

The breast cancer screening initiatives by government bodies and supportive programs introduced by public organizations are anticipated to stimulate the growth of the global breast cancer therapeutics market. According to the WHO report, early detection of breast cancer assists in minimizing the breast cancer mortality rate and accelerates the survival rate among patients who have breast cancer. Numerous government bodies across the globe encourage people to undergo breast cancer screening, especially women aged 50 and over. The screening initiatives and awareness programs are projected to propel the utilization of drugs for the effective treatment of breast cancer, driving the global breast cancer therapeutics market growth over the forecast period.

Escalating Demand for Targeted Therapy Supports the Market Growth

Treatment for breast cancer across the globe is a challenging task for any medical oncologist. The availability of treatment and choice varies from patient to patient. Targeted therapy is preferred over any other therapy as it precisely targets the breast cancer cells without damaging the surrounding healthy cells. The targeted therapy aids medical professionals in overcoming numerous limitations posed by traditional treatments. Targeted therapy also helps oncologists focus more on preventive care than reactive care. This therapy enhances the treatment efficiency in patients diagnosed with advanced stages of breast cancer, which further contributes to the growth of the global breast cancer therapeutics market.

Market Segmentation

The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The chemotherapy drugs are further divided into anthracyclines, taxanes, and antimetabolites, and hormone therapy is divided into selective estrogen receptor modulators, aromatase inhibitors, and others. Also, the targeted therapy is divided into monoclonal antibodies, a tyrosine kinase inhibitor, Herceptin, and others. Based on the end users, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among the North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG are the leading market players contributing the growth of the global breast cancer therapeutics market.

Report Scope

In this report, global breast cancer therapeutics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Diagnostics Market, By Therapy:

  • Chemotherapy
    • Anthracyclines
    • Taxanes
    • Antimetabolites
    • Others
  • Hormone Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Others
  • Immunotherapies
  • Targeted Therapy
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitor
    • Herceptin
    • Others
  • Others

Breast Cancer Diagnostics Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Breast Cancer Diagnostics, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Therapy Overview

2. Research Methodology

3. Impact of COVID-19 on Global Breast Cancer Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Global Breast Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 6.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 6.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 6.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Company (2021)
    • 6.2.4. By Region
  • 6.3. Product Market Map

7. North America Breast Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 7.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 7.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 7.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 7.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Breast Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Breast Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Breast Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By End User

8. Europe Breast Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 8.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 8.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 8.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 8.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Breast Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By End User
    • 8.3.2. Germany Breast Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By End User
    • 8.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By End User
    • 8.3.4. Italy Breast Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By End User
    • 8.3.5. Spain Breast Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By End User

9. Asia-Pacific Breast Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 9.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 9.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 9.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 9.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Breast Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By End User
    • 9.3.2. India Breast Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By End User
    • 9.3.3. Japan Breast Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By End User
    • 9.3.4. South Korea Breast Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By End User
    • 9.3.5. Australia Breast Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By End User

10. South America Breast Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 10.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 10.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 10.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 10.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By End User
    • 10.3.2. Argentina Breast Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By End User
    • 10.3.3. Colombia Breast Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By End User

11. Middle East and Africa Breast Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 11.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 11.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 11.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 11.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Breast Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By End User
    • 11.3.2. Saudi Arabia Breast Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By End User
    • 11.3.3. UAE Breast Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Novartis AG
  • 14.2. Pfizer Inc.
  • 14.3. Eli Lilly & Company
  • 14.4. Merck Co. & Inc.
  • 14.5. GlaxoSmithKline, Plc.
  • 14.6. AstraZeneca Plc.
  • 14.7. Bristol-Myers Squibb Company
  • 14.8. Halozyme Inc.
  • 14.9. Eisai Co., Ltd.
  • 14.10. Fresenius Kabi AG

15. Strategic Recommendations